Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global leader in eye health products with a market capitalization of $6.55 billion, has been navigating a complex market landscape in 2024.

Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic ...

Papa took over as the new CEO of Bausch & Lomb, and oversaw the $2.5bn acquisition of the dry eye disease therapy XIIDRA and other ophthalmology assets from Swiss Pharma giant Novartis AG (NVS ...

After hours: December 27 at 4:00:29 PM EST Loading Chart for BLCO ...

Elios Vision former chairman and CEO Elliot Friedman said: “Bausch + Lomb’s extensive reach in cataract surgery will introduce ELIOS to a broader range of eye care professionals and help ...

Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global leader in eye health products with a market capitalization of $6.55 billion, has been navigating a complex market landscape in 2024. The ...

Bausch + Lomb has a portfolio of about 400 products including contact lenses, lens care products, eye care products and other products. The company was spun off from Bausch Health Companies ...

Questions about whether the company could remain solvent without Bausch + Lomb have complicated the separation. Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady ...

Bausch + Lomb Corp (NYSE:BLCO; TSX:BLCO), a global leader in eye health products, has recently experienced a mix of positive developments and challenges that have caught the attention of investors ...